Usage: Zinc acetate is indicated for the maintenance treatment of patients with Wilson’s disease who have previously received initial therapy with a chelating agent.
Usage: KHINDIVI is indicated for replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency. It is not approved for stress dosing; another hydrocortisone product should be used in such cases.